Man smiling behind laptop)

CSL Behring Newsroom

Recent News Releases

CSL and Vitaeris Announce Strategic Partnership with Option to Acquire
05 Dec 2017 News Release

The two companies have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid organ transplant rejection.

Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting
29 Oct 2017 News Release

A subgroup analysis of data from the Phase III COMPACT trial showed 98 percent median reduction in hereditary angioedema (HAE) attacks per month in subjects who experienced at least one attack per week while on placebo

New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
24 Oct 2017 News Release

- HAEGARDA is the first and only subcutaneous preventive treatment option for HAE in the US
- Oral presentation will highlight the preventive effect of HAEGARDA in HAE patients with a high frequency of attacks

CSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourages Other Businesses to Do the Same
12 Oct 2017 News Release

There are more than 350,000 cardiac arrests annually in the U.S.; nearly 90 percent are fatal but when CPR is administered immediately, chances of survival can triple.

Japan’s Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring’s Novel Recombinant Haemophilia A Treatment
28 Sep 2017 News Release

AFSTYLA® is the first and only single-chain recombinant factor VIII specifically designed to treat hemophilia A

Want to know more about how we are sharing stories of biotech's promise?

Read Vita

CSL Behring Media Contacts

Natalie de Vane

Corporate Inquiries
Phone: +1 610-878-4468

Greg Healy

Product Inquiries
(Bleeding disorders and Warfarin reversal)
Phone: +1 610-878-4841

Christopher Florentz

Corporate Inquiries
Phone: +1 610-878-4316

Jennifer Purdue

Product Inquiries
(Immune disorders, Alpha-1, HAE)
Phone: +1 610-878-4802

CSL Behring Production Sites

Sandra Ruckstuhl

Bern, Switzerland
Phone: +41 31-344-1124

Maureen E. Powell

Kankakee, Illinois, USA
Phone: +1 815-935-3120

Stephanie Fuchs

Marburg, Germany
Phone: +49 6421 39-5972

Christina Hickie

Broadmeadows, Victoria, Australia
Phone: +61 429 609 762

Past News Releases by Year

News Archives 2016 pdf
News Archives 2015 pdf
News Archives 2014  pdf
News Archives 2013  pdf
News Archives 2012  pdf

Get our latest news in your inbox
First name
Last name


You have now been added
to the CSL Behring news list